A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
Summary
Third Opinion Trial Synopsis:
This study is comparing two treatments for a type of cancer called multiple myeloma. The first treatment involves using three drugs, and then giving the patient a single dose of another drug. The second treatment involves using two drugs for a longer period of time. The study is trying to find out which treatment helps people live longer without the cancer getting worse.
This study is comparing two treatments for a type of cancer called multiple myeloma. The first treatment involves using three drugs, and then giving the patient a single dose of another drug. The second treatment involves using two drugs for a longer period of time. The study is trying to find out which treatment helps people live longer without the cancer getting worse.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as initial therapy in terms of Progression Free Survival (PFS).
The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as initial therapy in terms of Progression Free Survival (PFS).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: